These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26577335)

  • 41. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
    Leuenberger P; Sauty A; Rochat T
    Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ; Singh H; Diaz J; Peters JI
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma.
    Milgrom H; Fowler-Taylor A; Vidaurre CF; Jayawardene S
    Curr Med Res Opin; 2011 Jan; 27(1):163-9. PubMed ID: 21121874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment.
    Baena-Cagnani CE; Teijeiro A; Canonica GW
    Curr Opin Allergy Clin Immunol; 2015 Jun; 15(3):267-71. PubMed ID: 25899697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
    Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
    Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO; Strohner P; Zimmer KP; Lindemann H
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Paggiaro PL
    J Investig Allergol Clin Immunol; 2017; 27(6):388-391. PubMed ID: 29199967
    [No Abstract]   [Full Text] [Related]  

  • 52. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
    Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
    Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Omalizumab's Impact on Total and Allergen-Specific IgE Levels: A Polyclonal Story.
    Eckl-Dorna J
    Int Arch Allergy Immunol; 2016; 169(2):69-70. PubMed ID: 27035498
    [No Abstract]   [Full Text] [Related]  

  • 55. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis.
    Maykut RJ; Kianifard F; Geba GP
    J Asthma; 2008 Apr; 45(3):173-81. PubMed ID: 18415822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.
    Hayden ML
    J Am Acad Nurse Pract; 2007 Sep; 19(9):439-49. PubMed ID: 17760568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real life study of three years omalizumab in patients with difficult-to-control asthma.
    López Tiro JJ; Contreras EA; del Pozo ME; Gómez Vera J; Larenas Linnemann D
    Allergol Immunopathol (Madr); 2015; 43(2):120-6. PubMed ID: 24780091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.